HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NDI Or GRAS? Supplement Label But A Drug Claim? Answers Unclear For Some Regulatory Questions

Executive Summary

“We try to interpret the language that is given to us and if Congress would make it more clear to us, we would absolutely carry that forward,” ODSP's Cara Welch says about whether FDA regulations require NID notifications or self-GRAS submissions for dietary ingredients yet to be used in supplements.

You may also be interested in...

Court Suggests Critics Ask Congress To Change FDA's GRAS Rule – Same For NDI Notifications?

Federal judge suggests consumer health and environmental advocacy groups made strong arguments about potential for unsafe ingredients in foods available in the US through the self-GRAS process, but FDA adopted and exercises the rule entirely in line with congressional intent of the authorizing legislation.

Potential For US Requiring Supplement Registration Underscored During FDA’s Hiatus From Inspections

FDA’s pause in facility inspections could prompt draft legislation for mandatory supplement product registration. It told industry groups it’s working on language for legislation to give it a better handle on products in the market and facilities with problems, says CRN head Steve Mister.

GRAS Self-Affirmation Fades As Sound Strategy Under FSMA

Experts at a FDLI conference say Food Safety Modernization Act obligations should convince companies to move beyond self-affirming food ingredients as “generally recognized as safe” without notifying FDA. While the GRAS process generally is considered effective, it lacks transparency in some areas.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts